Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization
- Conditions
- Interventions
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 155
- Registration Number
- NCT01874561
- Locations
- 🇺🇸
Teva Investigational Site 10565, Lenexa, Kansas, United States
Effects of SQ109 on QTc Interval in Healthy Subjects
- Conditions
- Interventions
- Locations
- 🇺🇸
Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine, Cleveland, Ohio, United States
Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs
- Conditions
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01871701
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyounggi, Korea, Republic of
A Study to Investigate the Effect of PH-797804 on QTc Interval
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT01862887
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2014-11-12
- Lead Sponsor
- ApoPharma
- Target Recruit Count
- 50
- Registration Number
- NCT01860703
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 136
- Registration Number
- NCT01839279
- Locations
- 🇺🇸
Covance- Dallas, Dallas, Texas, United States
A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2015-01-28
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01803399
Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials
- Conditions
- Interventions
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2013-08-28
- Target Recruit Count
- 1303
- Registration Number
- NCT01799356
- Locations
- 🇹🇷
T.C.S.B Mardin Women and Children Hospital, Mardin, Turkey
🇹🇷T.C.S.B. İstanbul Training Research Hospital, Samatya, Fatih, Turkey
🇹🇷T.C.S.B. Kanuni Sultan Suleyman Training Hospital, İstanbul, Kucukcekmece, Turkey
Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 648
- Registration Number
- NCT01792700
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
ANX-188 Thorough QT/QTc Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT01790087
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.